FONT-SIZE Plus   Neg

Novartis Unit Announces FDA Approval Of Simbrinza Suspension

Eye care company Alcon, a part of Swiss drug giant Novartis AG (NVS), Friday announced US Food and Drug Administration approval for Simbrinza Suspension, indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

Elevated intraocular pressure, or IOP, is the only modifiable risk factor for glaucoma, a group of eye diseases that lead to progressive damage of the optic nerve and can result in gradual, irreversible loss of vision, and eventually blindness, if left untreated. Glaucoma affects more than 2.2 million Americans and is the second-leading cause of preventable blindness worldwide.

Simbrinza is a fixed-dose combination medication that offers a wide range of
treatment possibilities due to its strong efficacy and ability to decrease
elevated IOP by 21- 35% In addition, it is the only available,
fixed-dose combination therapy for glaucoma in the US without a beta

The new ophthalmic suspension is a fixed-dose combination of a carbonic
anhydrase inhibitor (Brinzolamide 1.0%) and an alpha 2 adrenergic receptor
agonist (Brimonidine Tartrate 0.2%). It combines the two drugs into one
multi-dose bottle, helping to reduce the medication burden for glaucoma

The FDA approval of Simbrinza is based on data from two pivotal Phase III
clinical trials with about 1,300 patients. The studies evaluated
the safety and efficacy of a fixed-dose combination of Brinzolamide 1.0% and
Brimonidine 0.2%, administered three times daily, compared to separate three-
times-per-day dosing of one or the other component. Both studies met
their primary endpoint and demonstrated that Simbrinza is statistically superior
compared to either component regarding mean IOP at Month 3 for all time points.

The most frequently reported adverse reactions in patients treated with Simbrinza were blurred vision, eye irritation, dysgeusia (bad taste), dry mouth and eye allergy.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

comments powered by Disqus
Follow RTT